As DLK1 functions as a selective inhibitor of ACVR2B, it may have the potential to be adapted as a more targeted therapy for counteracting the loss of muscle associated with anti-obesity drugs, muscle wasting disorders, or cachexia. Here, ACVR2B is linked to obesity due to melanocortin 4 receptor deficiency.